Researchers find genetic basis for important risk factor in blinding eye disease: Bethesda, Maryland Wednesday, December 10, 2025, 15:30 Hrs [IST] A study funded in part by the Na ...
Apellis Pharmaceuticals, Inc. ( APLS) Citi Annual Global Healthcare Conference 2025 December 2, 2025 2:30 PM EST ...
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 BioPhase 2 basket trial planned to evaluate ...
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is one of the best upside stocks to buy now. On November 12, Apellis ...
Chittenango Falls State Park sits quietly near Cazenovia, offering one of the most breathtaking natural displays in the Empire State without the crowds that plague more famous destinations.
Pneumonia, a leading cause of global morbidity and mortality, continues to pose significant clinical and public health challenges, particularly amid the ...
Gibson Southern and Heritage Hills are one victory from a trip to Lucas Oil Stadium. A look at each matchup and semi-state ...
CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...
FDA approval enables Complement Therapeutics to start the Opti-GAIN phase 1/2 trial for CTx001 in GA secondary to AMD. CTx001 is an AAV-based gene therapy delivering a truncated Complement Receptor 1 ...
The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback